SABCS 2019 highlights

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer

Imaging for women who are high risk of breast cancer

Adding S-1 to post-operative endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Implementation of genetic testing in breast cancer patients

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC

Breast cancer screening and treatment in Brazil

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women